Philips' low-dose CT suite cleared by FDA for lung cancer screening

Philips announced today that its suite of CT solutions has received 501(k) clearance from the FDA for low-dose lung cancer screening.

As the leading cause of cancer death for both men and women in the U.S., lung cancer survival hinges on early detection. Screenings have been recommended for high-risk patients earlier in life, which has been shown to decrease mortality by as much as 20 percent.

FDA clearance of the full Philips CT suite—which includes 27 CT and PET/CT models as well as integrated software services—will help build on these efforts, according to the company’s CEO of diagnostic imaging, Rob Cascella, and will essentially allow any facility currently using the company’s CT models to operate as a lung cancer screening center.

"Our robust portfolio of CT solutions offers our customers in the United States a turnkey approach to lung cancer screening," Cascella said in a press release. "This is a complementary offering to utilize existing systems to bring low-dose CT screening to healthcare facilities of all sizes who want to drive earlier detection for patients at high risk for lung cancer."

Read the full announcement.